First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC

Phase IV study of gefitinib used as first-line treatment in Caucasian patients with epidermal growth factor receptor mutation-positive locally advanced/metastatic non-small cell lung cancer indicate the treatment is effective and well tolerated. The findings were presented by Dr Jean-Yves Douillard, professor of medical oncology at University of Nantes and Department of Medical Oncology, Institut de Cancérologie de l’Ouest - René Gauducheau, St Herblain, France on behalf of multinational investigators team at the European Multidisciplinary Conference in Thoracic Oncology (EMCTO), held 9-11 May, 2013 in Lugano, Switzerland. Read more here.